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Systemic combination chemotherapy, such as the methotrexate, vinblastine, doxorubicin and cisplatin
(MVAC) regimen, has shown certain activity in advanced bladder cancer, but is associated with a signiﬁcant
toxicity burden, with a treatment-related mortality of about 4%. Therefore, a great deal of interest has been
focused on the gemcitabine-cisplatin (GC) combination chemotherapy which showed the same antitumor
effect as MVAC chemotherapy with far less toxicity. Indeed, the GC regimen is now frequently
administered as the ﬁrst-line chemotherapy against metastatic bladder cancer. For the present, GC/MVAC
regimens constitute alternative platform chemotherapy, until new evidence based strategy can be
demonstrated. Accordingly it is important to be able to predict whether a regimen is effective in each
patient with bladder cancer before the initiation of chemotherapy. Clinicopathological factors as the
Karnofsky performance status and the presence of visceral metastases are well-established prognostic markers
for poor survival. However, they are inadequate to predict the optimal therapeutic regimen for each
individual patient. As for the predictive marker of cisplatin, ERCC1 may predict survival in bladder cancer
treated by platinum-based therapy. The predictive potential of gemcitabine has not been previously
considered in advanced bladder cancer treated by gemcitabine-combined systemic chemotherapy. In our
retrospective study, the predictive value of a high expression level of hENT1 was assessed in bladder cancer
treated by gemcitabine combined combination chemotherapy.
(Hinyokika Kiyo 57 : 157-161, 2011)
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れわれは GEM に関連する予後・効果予測マーカーと
して，GEM が細胞内に取り込まれる際の key mole-
cule とされている human equilibrative nucleoside trans-
porter 1 (hENT1) の発現についての後ろ向き研究を
行った．
対 象 と 方 法
対象症例は2002年 6月∼2009年 7月までの期間に，
gemcitabine (GEM) と cisplatin (CDDP) を含む 多剤
併用化学療法 (gemcitabine-cisplatin : 以下 GC 療法お
よびgemcitabine-cisplatin-paclitaxel : 以下 GCT 療法）
を施行した評価可能病変を有する転移性膀胱癌患者で
ある．GC 療法は GEM を 1,000 mg/m2 (day 1，8，
15），CDDP を 70 mg/m2 (day 2) に投与し 4週サイク
ルを原則とした．GCT 療法は GEM を 1,000 mg/m2
(day 1，8），CDDP を 70 mg/m2 (day 2），paclitaxel を














Fig. 1. Immunostaining of hENT1.












Pure TCC 23 (95.8)















計学的に解析した． 2群間の比較は Fisher の直接法
を使用し，生存に関しては全生存を Kaplan-Meyer 法









全摘が施行されていた (Table 1）．hENT1 の免疫組織








生存）と hENT1 の発現の関係は，Fig. 2に示した．
泌57,03,8-2
Fig. 2. Kaplan-Meier estimates of overall survival in metastatic bladder cancer patients treated with











ている excision repair cross complementing 1 (ERCC1)










的な取り込みには nucleoside transporter の存在が必須
である4)．数種類報告されている nucleoside transporter
の中でも最も重要な役割を果たしているとされている
のが human equilibrative nucleoside transporter 1 (hENT1)
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Table 2. Univariate analysis of baseline patient characteristics
No of Median survival months (95％CI) Hazard ratio (95％CI) P*
Age 0.213
＜65 9 15.5 (12.0-19.0) 2.075 (0.658- 6.542)
≧65 15 16.5 (10.8-22.1) 1
Performance status 0.028
0 9 22.7 (13.9-31.5) 1
≧1 15 13.3 (11.4-15.2) 3.160 (1.141-10.342)
Past history of TCx 0.487
Present 12 16.6 (13.2-19.9) 1
Absent 12 13.6 (10.5-16.8) 1.409 (0.536- 3.710)
Visceral metastasis 0.043
Present 13 13.6 (11.6-15.6) 3.422 (1.041-11.244)
Absent (LN meta) 11 22.7 ( 8.0-37.5) 1
Chemotherapy 0.42
GC 9 16.6 ( 9.2-33.1) 0.595 (0.168- 2.102)
GCT 15 15.5 (11.9-19.1) 1
ERCC1 0.163
Low 12 17.3 (12.7-21.9) 1
High 12 13.6 (11.6-15.7) 2.043 (0.749- 5.577)
hENT1 0.003
Low 14 12.3 ( 7.6-16.9) 5.898 (1.802-19.301)
High 10 23.0 (16.3-29.6) 1
* log-rank test.
である．これまで，膵癌や肺癌など他の固形癌におい


































指針はない．Molecular pharmacology marker などを臨
床導入した上で，テーラーメイド治療の確立が望まれ
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